Webinar: COVID-19 and Alcohol-associated Liver Disease

Content Contributors

• American Association for the Study of Liver Diseases
• AASLD COVID-19 Clinical Oversight Subcommittee
• AASLD Alcohol-associated Liver Disease SIG

Presenters

• Brenda Curtis, PhD, MsPH
  NIH / National Institute on Drug Abuse
• Andrew Moon, MD, MPH
  University of North Carolina, Division of Gastroenterology and Hepatology

Moderators

• Pranoti Mandrekar, PhD, FAASLD
  University of Massachusetts Medical School
• Ashwani K. Singal, MD, MS, FACG, FAASLD
  University of South Dakota

Panelist

• Elizabeth C. Verna, MD, MS
  Columbia University Medical Center

Details

Alcohol-associated liver disease (ALD) is the leading etiology for end-stage liver disease, acute-on-chronic liver failure, and need for liver transplantation. Alcohol use is the most important modifiable risk factor for ALD.

Since February-March 2020, Covid-19 pandemic has altered lifestyle across the world including the US, which includes healthcare. Apart from general effects of COVID-19 pandemic on care of ALD patients, social distancing and many other factors have impacted patient behavior including alcohol consumption.

Attendees of this webinar will:

• Recognize the impact of COVID-19 on alcohol consumption and alcohol use disorder (AUD)
• Learn the impact of COVID-19 on the frequency and severity of ALD in both pre- and post-transplant settings.